Hoth Therapeutics' Losses Widen Amid Soaring R&D Costs

Ticker: HOTH · Form: 10-Q · Filed: 2025-11-12T00:00:00.000Z

Sentiment: bearish

Topics: Biotechnology, Clinical Stage, Net Loss, R&D Expenses, Cash Burn, Equity Financing, Going Concern

TL;DR

**HOTH is burning cash at an alarming rate with no revenue in sight; avoid unless you're a high-risk gambler on early-stage biopharma.**

AI Summary

Hoth Therapeutics, Inc. reported a net loss of $4,105,801 for the three months ended September 30, 2025, significantly wider than the $2,229,017 loss for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $9,781,113, compared to $6,085,710 in the prior year. The company's research and development expenses surged to $4,631,791 for the nine months ended September 30, 2025, up from $2,210,141 in 2024, representing a 109.6% increase. General and administrative expenses also rose to $5,124,539 from $3,902,509, a 31.3% increase. Hoth Therapeutics had no net revenues for either period. Cash and cash equivalents increased to $7,847,911 as of September 30, 2025, from $7,038,923 at December 31, 2024, primarily due to $8,760,556 in financing activities, including $5,625,000 from warrant exercises and $3,511,556 from common stock issuance. The company also invested $300,000 in crypto assets, which incurred an unrealized loss of $25,305. The accumulated deficit reached $70.2 million, indicating continued reliance on equity financing.

Why It Matters

Hoth Therapeutics' escalating net losses and significant cash burn, driven by a 109.6% increase in R&D expenses, signal a high-risk investment for shareholders. While the company successfully raised $8.76 million through financing activities, including warrant exercises and stock issuance, this dilutes existing shareholders and highlights a continued reliance on external capital. The competitive biopharmaceutical landscape demands substantial investment in drug development, but Hoth's lack of revenue and growing deficit raise questions about its long-term viability and ability to bring products to market. Investors should weigh the potential of its drug candidates against the company's current financial trajectory and the competitive pressures from larger, more established pharmaceutical firms.

Risk Assessment

Risk Level: high — Hoth Therapeutics reported an accumulated deficit of $70.2 million as of September 30, 2025, and a net loss of $9,781,113 for the nine months ended September 30, 2025. The company has no net revenues and relies entirely on equity financing, indicating a significant going concern risk without continuous capital raises.

Analyst Insight

Investors should exercise extreme caution and consider HOTH a highly speculative investment. Monitor future financing activities closely for further dilution and assess the progress of their clinical pipeline against the rapid cash burn. New investors should likely avoid, while existing investors should re-evaluate their position.

Financial Highlights

debt To Equity
0.12
revenue
$0
operating Margin
N/A
total Assets
$9.24M
total Debt
$1.01M
net Income
-$9.78M
eps
N/A
gross Margin
N/A
cash Position
$7.85M
revenue Growth
N/A

Revenue Breakdown

SegmentRevenueGrowth
Net Revenues$0N/A

Key Numbers

Key Players & Entities

FAQ

What were Hoth Therapeutics' net revenues for the nine months ended September 30, 2025?

Hoth Therapeutics, Inc. reported $0 in net revenues for the nine months ended September 30, 2025, consistent with the prior year, indicating its pre-commercial stage.

How much did Hoth Therapeutics spend on research and development for the nine months ended September 30, 2025?

Hoth Therapeutics' research and development expense for the nine months ended September 30, 2025, was $4,631,791, a significant increase from $2,210,141 in the same period of 2024.

What was Hoth Therapeutics' net loss for the three months ended September 30, 2025?

For the three months ended September 30, 2025, Hoth Therapeutics reported a net loss of $4,105,801, which is a substantial increase from the $2,229,017 net loss in the comparable 2024 period.

What is Hoth Therapeutics' accumulated deficit as of September 30, 2025?

As of September 30, 2025, Hoth Therapeutics had an accumulated deficit of $70,191,154, reflecting the company's cumulative losses since inception.

How did Hoth Therapeutics fund its operations during the nine months ended September 30, 2025?

Hoth Therapeutics primarily funded its operations through financing activities, generating $8,760,556 from proceeds from common stock issuance ($3,511,556) and exercise of warrants ($5,625,000) during the nine months ended September 30, 2025.

What are the key drug candidates Hoth Therapeutics is developing?

Hoth Therapeutics is developing HT-001 for cancer drug side effects, HT-KIT for mast-cell derived cancers and anaphylaxis, HT-ALZ for Alzheimer's, BioLexa for atopic dermatitis, HT-004 for asthma and allergies, and HT-VA for obesity.

Does Hoth Therapeutics have enough cash to fund operations for the next 12 months?

Hoth Therapeutics believes its current cash of $7,847,911 is sufficient to fund operations for at least the next 12 months from the issuance date of the financial statements, but acknowledges the need for additional funding for long-term development.

What was the impact of crypto assets on Hoth Therapeutics' financials?

Hoth Therapeutics purchased $300,000 in crypto assets, which resulted in an unrealized loss of $25,305 for the nine months ended September 30, 2025.

How many common shares of Hoth Therapeutics were outstanding as of November 11, 2025?

The number of shares of Hoth Therapeutics' common stock outstanding at November 11, 2025, was 15,514,312, up from 8,042,747 shares at December 31, 2024.

What is Hoth Therapeutics' strategy for raising additional capital?

Hoth Therapeutics plans to raise additional funding through strategic relationships, public or private equity or debt financings, grants, or other arrangements, as outlined in their liquidity and capital resources section.

Risk Factors

Industry Context

Hoth Therapeutics operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space typically focus on developing novel therapeutics, which involves significant R&D investment and long development cycles. Success is often dependent on clinical trial outcomes, regulatory approvals, and the ability to secure substantial funding to advance drug candidates through various stages of development.

Regulatory Implications

As a biotechnology company, Hoth Therapeutics is subject to stringent regulatory oversight from bodies like the FDA. Delays or failures in clinical trials, or issues with manufacturing and marketing approvals, can significantly impact the company's prospects. The company's pre-commercial stage means it faces the inherent risk of not obtaining necessary regulatory clearances for its pipeline products.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Accumulated deficit
The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical unprofitability and reliance on external funding, standing at $70.2 million as of September 30, 2025.)
Crypto assets, at fair value
Digital assets held by the company that are valued based on their current market price. (Represents a new, potentially volatile investment for Hoth Therapeutics, with $300,000 invested and an unrealized loss of $25,305 as of September 30, 2025.)
Warrant exercises
The act of a warrant holder buying the underlying stock at a specified price, providing capital to the company. (A significant source of financing for Hoth Therapeutics, contributing $5.63 million to cash from financing activities in the nine months ended September 30, 2025.)
Common stock issuance
The sale of new shares of the company's common stock to investors. (Another key source of capital for Hoth Therapeutics, contributing $3.51 million in the nine months ended September 30, 2025.)
Operating lease right-of-use asset, net
An asset representing the right to use a leased asset over the lease term, net of accumulated amortization. (Reflects the company's use of leased assets, with a value of $11,464 as of September 30, 2025, down from $31,075 at the end of 2024.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period ended September 30, 2024, Hoth Therapeutics has experienced a substantial increase in its net loss, widening from $6.09 million to $9.78 million. This is primarily driven by a 109.6% surge in research and development expenses to $4.63 million and a 31.3% rise in general and administrative expenses to $5.12 million. While cash and cash equivalents have increased to $7.85 million due to robust financing activities, the company continues to generate no revenue, and its accumulated deficit has grown to $70.2 million, indicating a worsening financial performance and increased reliance on capital markets.

Filing Stats: 4,430 words · 18 min read · ~15 pages · Grade level 18.5 · Accepted 2025-11-12 16:16:53

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 1 ITEM 1.

Financial Statements

Financial Statements 1 Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 2 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 ITEM 4.

Controls and Procedures

Controls and Procedures 28

- OTHER INFORMATION

PART II - OTHER INFORMATION 29 ITEM 1.

Legal Proceedings

Legal Proceedings 29 ITEM 1A.

Risk Factors

Risk Factors 29 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 ITEM 3. Defaults Upon Senior Securities 30 ITEM 5. Other Information 31 ITEM 6. Exhibits 31

SIGNATURES

SIGNATURES 32 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains certain forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any statements in this Quarterly Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "believes," "will," "expects," "anticipates," "estimates," "predicts," "potential," "continues" "intends," "plans" and "would" or the negative of these terms or other comparable terminology. For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management and organizational structure are all forward-looking statements. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed in this Quarterly Report on Form 10-Q. Our business and ou

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS. HOTH THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2025 2024 (Unaudited) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 7,847,911 $ 7,038,923 Prepaid expenses and other current assets 1,073,641 605,948 Total Current Assets 8,921,552 7,644,871 NON-CURRENT ASSETS: Crypto assets, at fair value 274,695 - Operating lease right-of-use asset, net 11,464 31,075 Investment in joint ventures at fair value 36,819 36,819 Total Non-Current Assets 322,978 67,894 Total Assets $ 9,244,530 $ 7,712,765 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 400,067 $ 412,071 Accrued expenses 599,018 390,760 Operating lease liability, current portion 13,599 28,366 Total Current Liabilities 1,012,684 831,197 LONG-TERM LIABILITIES: Operating lease liability, less current portion - 2,709 Total Long-Term Liabilities - 2,709 Total Liabilities 1,012,684 833,906 Commitments and Contingencies (Note 8) STOCKHOLDERS' EQUITY: Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized; 3,000,000 shares undesignated; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024 - - Series A Convertible Preferred Stock, $ 0.0001 par value; 5,000,000 shares designated; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024 - - Series B Preferred Stock, $ 0.0001 par value; 2,000,000 shares designated; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024 - - Common stock, $ 0.0001 par value; 50,000,000 shares authorized; 15,127,622 and 8,042,747 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 1,513 804 Additional paid-in capital 78,410,459 67,279,033 Accumulated deficit ( 70,191,154 ) ( 60,410,041 ) Accumulated other comprehensive income 11,028 9,063 Total Stockholde

View on Read The Filing